ExLibris header image
SFX Logo
Title: PI3Kγ inhibition: towards an 'aspirin of the 21st century'?
Source:

Nature Reviews Drug Discovery [1474-1776] Rückle, Thomas yr:2006


Collapse list of basic services Basic
Full text
Full text available via Nature
GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Cantley, Lewis C C. "The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism." Nature reviews. Genetics 7.8 (2006): 606-19. Link to Full Text for this item Link to SFX for this item
2. Fruman, D A. "PI3K  Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic." Cancer Discovery 1.7 (2011): 562-572. Link to SFX for this item
3. Frantz, S. "Pipeline problems are increasing the urge to merge." Nature Reviews. Drug Discovery 5.12 (2006): 977-979. Link to Full Text for this item Link to SFX for this item
4. Cantley, Lewis C C. "Ras, PI(3)K and mTOR signalling controls tumour cell growth." Nature 441.7092 (2006): 424-430. Link to Full Text for this item Link to SFX for this item
5. Fukami, K. "Structure, regulation, and function of phospholipase C isozymes." The Journal of biochemistry 131.3 (2002): 293-9. Link to SFX for this item
6. Cantley, Lewis C C. "The phosphoinositide 3-kinase pathway." Science 296.5573 (2002): 1655-7. Link to SFX for this item
7. Lemmon, Mark A. "Membrane recognition by phospholipid-binding domains." Nature reviews. Molecular cell biology 9.2 (2008): 99-111. Link to Full Text for this item Link to SFX for this item
8. Manning, Brendan D D. "AKT/PKB signaling: Navigating downstream." Cell 129.7 (2007): 1261-74. Link to SFX for this item
9. Overington, John P. "How many drug targets are there?" Nature reviews. Drug discovery 5.12 (2006): 993-6. Link to Full Text for this item Link to SFX for this item
10. Wu, M. "DOCK2 Interacts with FLT3 and Modulates the Survival of FLT3-Expressing Leukemia Cells." Blood 124.21 (2014). Link to SFX for this item
11. Sheiner, L B B. "Learning versus confirming in clinical drug development." Clinical pharmacology and therapeutics 61.3 (1997): 275-91. Link to SFX for this item
12. Drews, J. "What's in a number?" Nature reviews. Drug discovery 5.12 (2006): 975-975. Link to Full Text for this item Link to SFX for this item
13. Frantz, S. "FDA publishes analysis of the pipeline problem." Nature reviews. Drug discovery 3.5 (2004): 379-379. Link to Full Text for this item Link to SFX for this item
14. Higgins, Matthew J. "The outsourcing of R&D through acquisitions in the pharmaceutical industry." Journal of financial economics 80.2 (2006): 351-383. Link to SFX for this item
15. Wullschleger, S. "TOR Signaling in Growth and Metabolism." Cell 127.3: 471-484. Link to SFX for this item
16. Luo, J. "Targeting the PI3K-Akt pathway in human cancer: rationale and promise." Cancer cell 4.4: 257-262. Link to SFX for this item
17. Cully, M. "Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis." Nature reviews. Cancer 6.3 (2006): 184-192. Link to Full Text for this item Link to SFX for this item
18. Vivanco, I. "The phosphatidylinositol 3-kinase-AKT pathway in human cancer." Nature reviews. Cancer 2.7 (2002): 489-501. Link to Full Text for this item Link to SFX for this item
19. Shaw, Reuben J J. "The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin." Science 310.5754: 1642-1646. Link to SFX for this item
20. Huelsken, J. "New aspects of Wnt signaling pathways in higher vertebrates." Current opinion in genetics & development 11.5 (2001): 547-53. Link to Full Text for this item Link to SFX for this item
View More...
View Less...
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.